Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 24 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

8 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
8(33.3%)
Phase 3
8(33.3%)
Phase 1
8(33.3%)
24Total
Phase 2(8)
Phase 3(8)
Phase 1(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT00488137Phase 3Completed

Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation

Role: lead

NCT00485940Phase 3Completed

Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic Constipation

Role: lead

NCT00483886Phase 3Completed

Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

Role: lead

NCT01674192Phase 1Completed

Prucalopride Subjects With Renal Impairment

Role: lead

NCT01674166Phase 1Completed

Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Role: lead

NCT01670669Phase 1Completed

Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Role: lead

NCT01134185Phase 1Completed

Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment

Role: lead

NCT01036893Phase 1Completed

M0001 Effects on Oral Contraceptive Plasma Levels

Role: lead

NCT01179607Phase 2Completed

Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia

Role: lead

NCT01070615Phase 3Completed

Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation

Role: lead

NCT00987844Phase 3Completed

Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

Role: lead

NCT00903747Phase 1Completed

Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters

Role: lead

NCT00793429Phase 1Completed

Safety Study of Prucalopride in Healthy Volunteers

Role: lead

NCT00793247Phase 2Completed

Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)

Role: lead

NCT00598338Phase 3Completed

Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic Constipation

Role: lead

NCT00575614Phase 2Completed

Prucalopride in Patients With Chronic Idiopathic Constipation

Role: lead

NCT00576511Phase 2Completed

Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation

Role: lead

NCT00577018Phase 3Completed

Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic Constipation

Role: lead

NCT00487422Phase 3Completed

Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic Constipation

Role: lead

NCT00488215Phase 1Completed

A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride

Role: lead